Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095570 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| SCHEMBL29441997 | 0.81 | ALDH1A1 (0.52) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| SCHEMBL63469 | 0.81 | ALDH1A1 (0.52) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| SCHEMBL2096428 | 0.78 | CA1 (0.33) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| SCHEMBL2096427 | 0.78 | CA1 (0.33) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| Hydrogen Sulfide SCHEMBL28274662 | 0.78 | ALDH1A1 (0.50) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| SCHEMBL18242098 | 0.76 | P2RX7 (0.38) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| Iodide SCHEMBL29093541 | 0.75 | ALDH1A1 (0.48) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| Bromide SCHEMBL29093546 | 0.75 | ALDH1A1 (0.48) | ALDH1A1TDP1POLBL3MBTL1MEN1 | |
| SCHEMBL5253369 | 0.74 | ALDH1A1 (0.38) | ALDH1A1TDP1POLBL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3315579-B1 | SURFACE TREATMENT AGENT INCLUDING PERFLUORO(POLY)ETHER GROUP-CONTAINING SILANE COMPOUND | DAIKIN IND LTD (JP) | 2024-05-01 | — | — | EP | claimed |
| EP-3088487-A1 | SURFACE TREATING AGENT INCLUDING PERFLUORO(POLY)ETHER-GROUP-CONTAINING SILANE COMPOUND | Daikin Industries, Ltd. (JP) | 2016-11-02 | — | — | EP | claimed |
| US-20190330192-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-31 | — | — | US | disclosed |
| EP-3558976-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| EP-1534281-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | Astrazeneca AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004006925-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| EP-0609058-B1 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0210571-A1 | Phosphonopyridines and their 1,4-dihydroderivatives | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1987-02-04 | — | — | EP | disclosed |
| US-4450298-A | Vapor phase catalytic hydrolysis of benzal chloride or its halogen- or trifluoromethyl-substitute to form benzaldehyde or substitute | CENTRAL GLASS COMPANY, LIMITED (JP) | 1984-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ALDH1A1 412/4885TDP1 4548/4885POLB 757/4885 |
| US-20190330192-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | AGPS, AASDHPPT, HPD | ALDH1A1 215/4885TDP1 2971/4885POLB 4763/4885 |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ADAM10, ADAM9, CTRL | ALDH1A1 3388/4885TDP1 1640/4885POLB 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.